JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has expanded its antihypertensive portfolio with the rollout of two new generic products in the United States. Teva said this week that it’s in the final stages of launch preparation for olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets, a generic version of Tribenzor tablets from Daiichi Sankyo. In addition,
JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has launched Rajani, an oral contraceptive, to pharmacies in the United States. Teva said Wednesday that Rajani (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.02 mg/0.451 mg, and levomefolate calcium tablets, 0.451 mg) is a generic version of Beyaz from Bayer. Rajani comes in a 28-day blister
NEW YORK — Another large deal has been struck between Allergan plc and Teva Pharmaceutical Industries Ltd. The companies on Wednesday announced the sale of Allergan’s Anda Inc. distribution business to Teva for $500 million. That came a day after they reported the close of Teva’s $39 billion acquisition of the Allergan’s legacy Actavis generics
NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business. The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares
HAYWARD, Calif. — Impax Laboratories Inc. has agreed to buy a portfolio of generic drug products from Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc for $586 million. Impax said Tuesday that the purchase — covering solid oral, inhalable, injectable and topical dosage forms — includes a group of 15 currently marketed generic products;
JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has begun an enterprisewide corporate identity program to build a global brand. Teva said Wednesday that it will introduce and implement the new brand within the company over the next 12 months. The company noted that it plans to unveil the brand to its 43,000 employees worldwide before
JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement
HOLZKIRCHEN, Germany — Sandoz has begun shipment of Glatopa, a one-time daily treatment for multiple sclerosis (MS), in the United States. The Novartis subsidiary said Thursday that the product (glatiramer acetate injection, 20 mg/ml) is the first generic version of Copaxone 20 mg, from Teva Pharmaceuticals. Developed in collaboration with Momenta and made in the
JERUSALEM — Teva Pharmaceutical Industries Ltd. has released generic versions of Actavis’ Actonel tablets, an osteoporosis medication, and of Amneal’s Lomedia 24 Fe, a women’s contraceptive, in the United States. Teva said Monday that its generic equivalent of Actonel (risedronate sodium) comes in dosages of 5 mg, 30 mg and 35 mg and that the
NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But
WASHINGTON — The Food and Drug Administration has approved the first generic versions of Otsuka Pharmaceutical’s Abilify (aripiprazole), an antipsychotic drug. The FDA said Tuesday that Teva Pharmaceuticals, Alembic Pharmaceuticals, Hetero Labs and Torrent Pharmaceuticals have been cleared to market generic aripiprazole in multiple strengths and dosage forms. With the approval, Teva Pharmaceutical Industries Ltd. on Tuesday announced the U.S.
POTTERS BAR, England — Mylan N.V. has rejected an unsolicited bid to be acquired by Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at more than $40 billion. Mylan said Monday that its board of directors unanimously voted against Teva’s offer, which was announced on April 21. Mylan stated that after a comprehensive review
JERUSALEM — Teva Pharmaceutical Industries Ltd. has made a bid to acquire Mylan N.V. in a cash-and-stock deal valued at about $40 billion. In announcing its offer Tuesday, Teva said its proposal is a more attractive option for shareholders of Mylan, which nearly two weeks ago made an unsolicited bid to buy Perrigo Co. plc
JERUSALEM and LA JOLLA, Calif. — Teva Pharmaceutical Industries Ltd. plans to purchase Auspex Pharmaceuticals Inc. in a deal valued at $3.2 billion. Teva said Monday that the agreement will bolster its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of medicines for people who live with movement disorders. A biopharmaceutical
